EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 718 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR From Scan to Scan: The Challenges of Living with Metastatic Cancer October 15, 2021 New obesity strategy is a ‘landmark day for the nation’s health’... July 27, 2020 49-Year-Old Breast Cancer Patient Grateful She Didn’t Wait Until 50 for... June 7, 2019 ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery February 28, 2024 Load more HOT NEWS Estimate of the Global Economic Cost of the Most Prevalent Cancers... Navigating Cancer Survivorship as a Transgender or Non-Binary Person Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations...
